Company news


Yingsheng Bio joins hands with Thermo Fisher to promote the industrialization of mass spectrometry

Inputtime:2020-03-12 10:10:33 Views:
On October 18, 2018, Beijing, the world leader inscience services, Thermo Fisher Scientific (hereafter referred to as: ThermoFisher) held the 2018 "China Innovation Day" in Beijing.ShandongYingsheng Biotechnology Co., Ltd. (hereinafter referred to as Yingsheng Bio)attended the event and demonstrated the liquid-tandem mass spectrometry(LC-MS/MS) and inductively coupled plasma mass spectrometry (ICP-MS) technologyfor human body. Innovative projects for the precise detection of vitamins andminerals,We will also cooperate with thecooperation plan to promote the industrialization of mass spectrometry productsand technologies in China, thus contributing to the research progress in thefield of precision diagnosis and treatment.

InnovativeDay Event Participant (Second 2: Assistant General Manager and ExecutiveDirector of Yingsheng Bio, Kong Ning)  


Innovationproject release (Assistant General Manager of Marketing and Marketing VicePresident Jiao Guobin)


     Withthe rapid development of mass spectrometry technology, mass spectrometry hasbecome an accurate and effective analytical tool in clinical testing. Theapplication of mass spectrometry in clinical testing mainly involves clinicalbiochemical tests, clinical immunology tests, clinical vitamin tests and clinicalmolecular biological diagnosis.Inthe United States, there are more than 400 clinical application of massspectrometry testing programs, including prenatal screening, newborn screening,drug monitoring, metabolite testing, vitamin testing and microbialidentification. In China, the clinical application of mass spectrometrytechnology started late, but it has become an important analytical tool forearly neonatal screening and clinical pharmacology. However, various factorssuch as high input cost of clinical mass spectrometry, high technical barriers,and relatively scarce talent reserves have always restricted the popularizationof clinical mass spectrometry technology in China.

    On the road to mass spectrometry products andtechnology in China, Yingsheng Bio has been at the forefront of the industry.For the future development of mass spectrometry technology, Yingsheng Bio andThermo Fisher have a common understanding. The two sides work closely togetherto promote the deep integration of high technology and accelerate thecombination of transformation capability and service capability. Yingsheng Biowill be launched in the second half of 18 years. A mass spectrometer above themid-end.Yingsheng Bio has been focusing on theresearch and development of the clinical application of tandem massspectrometry platform for many years, and has gradually promoted it to theapplication of precision diagnosis and treatment. At present, it has carriedout extensive screening of genetic metabolic diseases and fourteen vitamins invarious medical institutions across the country.Inthe future, Yingsheng Bio will also launch more clinical application solutionsbased on mass spectrometry platform, and gradually realize the whole industrychain from diagnostic reagents to artificial intelligence processing platformsto testing methods and testing instruments.